These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9100218)

  • 1. Simvastatin further enhances the hypocholesterolemic effect of soy protein in rabbits.
    Giroux I; Lavigne C; Moorjani S; Jacques H
    J Am Coll Nutr; 1997 Apr; 16(2):166-74. PubMed ID: 9100218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
    Conde K; Pineda G; Newton RS; Fernandez ML
    Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
    Krause BR; Newton RS
    Atherosclerosis; 1995 Oct; 117(2):237-44. PubMed ID: 8801869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
    Qin W; Infante J; Wang SR; Infante R
    Biochim Biophys Acta; 1992 Jul; 1127(1):57-66. PubMed ID: 1627634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of fish protein as compared to casein and soy protein on serum and liver lipids, and serum lipoprotein cholesterol levels in the rabbit.
    Bergeron N; Jacques H
    Atherosclerosis; 1989 Aug; 78(2-3):113-21. PubMed ID: 2783196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hypercholesterolemic effect of cod protein is reduced in the presence of high dietary calcium.
    Jacques H; Lavigne C; Desrosiers T; Giroux I; Hurley C
    Can J Physiol Pharmacol; 1995 Apr; 73(4):465-73. PubMed ID: 7671189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipids, lipoproteins and hepatic 3-hydroxy-3-methylglutaryl CoA reductase activities of rabbits during adaptation to atherogenic semi-purified diets.
    Bauer JE
    Artery; 1988; 15(3):140-62. PubMed ID: 3365122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(2):247-57. PubMed ID: 2736571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of simvastatin and fenofibrate on the fatty acid composition of hypercholesterolaemic patients.
    Agheli N; Jacotot B
    Br J Clin Pharmacol; 1991 Oct; 32(4):423-8. PubMed ID: 1958434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.
    Schulzeck P; Bojanovski M; Jochim A; Canzler H; Bojanovski D
    Lancet; 1988 Mar; 1(8586):611-3. PubMed ID: 2894548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin.
    Morand OH; Aebi JD; Dehmlow H; Ji YH; Gains N; Lengsfeld H; Himber J
    J Lipid Res; 1997 Feb; 38(2):373-90. PubMed ID: 9162756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients.
    Wanner C; Lubrich-Birkner I; Summ O; Wieland H; Schollmeyer P
    Nephron; 1992; 62(1):40-6. PubMed ID: 1436290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of long-term treatment with simvastatin on plasma lipids and lipoproteins in patients with primary hypercholesterolemia.
    Thiery J; Creutzfeldt C; Creutzfeldt W; Walli AK; Seidel D
    Klin Wochenschr; 1990 Aug; 68(16):814-22. PubMed ID: 2214604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A soy protein diet alters hepatic lipid metabolism gene expression and reduces serum lipids and renal fibrogenic cytokines in rats with chronic nephrotic syndrome.
    Tovar AR; Murguía F; Cruz C; Hernández-Pando R; Aguilar-Salinas CA; Pedraza-Chaverri J; Correa-Rotter R; Torres N
    J Nutr; 2002 Sep; 132(9):2562-9. PubMed ID: 12221209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simvastatin, transdermal patch, and oral estrogen-progestogen preparation in early-postmenopausal hypercholesterolemic women: a randomized, placebo-controlled clinical trial.
    Vigna GB; Donegà P; Zanca R; Barban A; Passaro A; Pansini F; Bonaccorsi G; Mollica G; Fellin R
    Metabolism; 2002 Nov; 51(11):1463-70. PubMed ID: 12404199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simvastatin: a review of its pharmacology and clinical use.
    Mauro VF; MacDonald JL
    DICP; 1991 Mar; 25(3):257-64. PubMed ID: 2028634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced cellular metabolism of very low density lipoprotein by simvastatin. A novel mechanism of action of HMG-CoA reductase inhibitors.
    Sehayek E; Butbul E; Avner R; Levkovitz H; Eisenberg S
    Eur J Clin Invest; 1994 Mar; 24(3):173-8. PubMed ID: 8033951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.